Gregg W Stone

List of Publications by Citations

495 papers	42,102 citations	102 h-index	198 g-index
541 ext. papers	53,055 ext. citations	9.5 avg, IF	7.19 L-index

#	Paper	IF	Citations
495	A prospective natural-history study of coronary atherosclerosis. *New England Journal of Medicine*, **2011**, 364, 226-35	59.2	2044
494	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 75, 2950-2973	15.1	1682
493	Bivalirudin during primary PCI in acute myocardial infarction. *New England Journal of Medicine*, **2008**, 358, 2218-30	59.2	1457
492	Bivalirudin for patients with acute coronary syndromes. *New England Journal of Medicine*, **2006**, 355, 2203-16	59.2	1167
491	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *New England Journal of Medicine*, **2018**, 379, 2307-2318	59.2	1160
490	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet, The*, **2007**, 370, 937-48	40	1141
489	Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *Journal of the American College of Cardiology*, **2020**, 75, 2352-2371	15.1	1109
488	Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation*, **1999**, 100, 1872-8	16.7	1016
487	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. *Lancet, The*, **2012**, 379, 1393-402	40	727
486	Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *New England Journal of Medicine*, **2010**, 362, 1663-74	59.2	700
485	Initial Invasive or Conservative Strategy for Stable Coronary Disease. *New England Journal of Medicine*, **2020**, 382, 1395-1407	59.2	642
484	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet, The*, **2013**, 382, 614-23	40	606
483	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. *New England Journal of Medicine*, **2016**, 375, 2223-2235	59.2	603
482	Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2005**, 294, 1215-23	27.4	590
481	Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. *Journal of the American College of Cardiology*, **2005**, 45, 995-8	15.1	586
480	Effect of platelet inhibition with cangrelor during PCI on ischemic events. *New England Journal of Medicine*, **2013**, 368, 1303-13	59.2	560
479	Intravenous platelet blockade with cangrelor during PCI. *New England Journal of Medicine*, **2009**, 361, 2330-41	59.2	480

478	A risk score to predict bleeding in patients with acute coronary syndromes. *Journal of the American College of Cardiology*, **2010**, 55, 2556-66	15.1	479
477	Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *JAMA - Journal of the American Medical Association*, **2008**, 299, 1903-13	27.4	477
476	Platelet inhibition with cangrelor in patients undergoing PCI. *New England Journal of Medicine*, **2009**, 361, 2318-29	59.2	454
475	Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2005**, 293, 1063-72	27.4	438
474	Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. *Circulation*, **2005**, 112, 2364-72	16.7	417
473	Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1817-26	27.4	373
472	Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *Journal of the American College of Cardiology*, **2005**, 45, 1397-405	15.1	367
471	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. *Lancet, The*, **2011**, 377, 2193-204	40	358
470	Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *Journal of the American College of Cardiology*, **2013**, 62, 1563-70	15.1	351
469	Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *European Heart Journal*, **2011**, 32, 1012-24	9.5	336
468	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Lancet, The*, **2007**, 369, 907-19	40	322
467	Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *European Heart Journal*, **2007**, 28, 1709-16	9.5	311
466	Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. *Journal of the American College of Cardiology*, **2015**, 65, 2496-507	15.1	309
465	Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. *Lancet, The*, **2016**, 388, 2618-2628	40	307
464	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. *Journal of the American College of Cardiology*, **2016**, 67, 2224-2234	15.1	306
463	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet, The*, **2018**, 391, 939-948	40	290
462	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. *Lancet, The* , **2015**, 385, 2371-82	40	275
461	Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. *JACC: Cardiovascular Interventions*, **2011**, 4, 654-64	5	274

460	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. *Journal of the American College of Cardiology*, **2015**, 66, 308-321	15.1	268
459	Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. *Journal of the American College of Cardiology*, **2017**, 69, 345-357	15.1	267
458	Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. *Circulation*, **2014**, 129, 463-70	16.7	267
457	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. *New England Journal of Medicine*, **2019**, 381, 1820-1830	59.2	265
456	Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. *Journal of the American College of Cardiology*, **2016**, 67, 1674-83	15.1	265
455	Coronary artery calcification: pathogenesis and prognostic implications. *Journal of the American College of Cardiology*, **2014**, 63, 1703-14	15.1	263
454	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. *European Heart Journal*, **2009**, 30, 1457-66	9.5	260
453	Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. *Journal of the American College of Cardiology*, **2015**, 65, 1231-1248	15.1	252
452	Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. *Circulation*, **2009**, 119, 680-6	16.7	245
451	Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. *Journal of the American College of Cardiology*, **2012**, 59, 2165-74	15.1	241
450	Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. *Circulation*, **2005**, 112, 2530-7	16.7	237
449	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. *Lancet, The*, **2013**, 382, 1981-92	40	234
448	Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. *Journal of the American College of Cardiology*, **2014**, 63, 1845-54	15.1	232
447	Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study. *Journal of the American College of Cardiology*, **2014**, 63, 1253-1261	15.1	229
446	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. *JAMA - Journal of the American Medical Association*, **2007**, 297, 591-602	27.4	226
445	Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. *Circulation*, **2000**, 101, 604-10	16.7	221
444	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. *Lancet, The*, **2016**, 387, 1277-89	40	217
443	Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. *Journal of the American College of Cardiology*, **2014**, 63, 299-307	15.1	217

442	Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. *Journal of the American College of Cardiology*, **2005**, 45, 1172-9	15.1	210
441	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. *American Heart Journal*, **2004**, 148, 764-75	4.9	210
440	A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. *European Heart Journal*, **2015**, 36, 3332-42	9.5	209
439	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. *Journal of the American College of Cardiology*, **2016**, 68, 1851-1864	15.1	201
438	Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. *Circulation*, **1999**, 100, 2400-5	16.7	200
437	Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. *Journal of the American College of Cardiology*, **2015**, 66, 2298-2309	15.1	192
436	Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. *Journal of the American College of Cardiology*, **2011**, 58, 704-11	15.1	192
435	Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. *JACC: Cardiovascular Imaging*, **2012**, 5, S62-72	8.4	188
434	Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. *Circulation*, **2005**, 111, 940-53	16.7	187
433	Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. *Circulation*, **2001**, 104, 642-7	16.7	174
432	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Circulation*, **2018**, 137, 2635-2650	16.7	172
431	A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. *Journal of the American College of Cardiology*, **2011**, 57, 1700-8	15.1	170
430	Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. *Circulation*, **2011**, 124, 893-900	16.7	163
429	Management of Coronary Disease in Patients with Advanced Kidney Disease. *New England Journal of Medicine*, **2020**, 382, 1608-1618	59.2	159
428	Characterization of Myocardial Injury in Patients With COVID-19. *Journal of the American College of Cardiology*, **2020**, 76, 2043-2055	15.1	159
427	Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. *Circulation: Cardiovascular Interventions*, **2011**, 4, 239-47	6	156
426	Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial. *Journal of the American College of Cardiology*, **2017**, 70, 2605-2617	15.1	155
425	The Primary Outcome Fails - What Next?. *New England Journal of Medicine*, **2016**, 375, 861-70	59.2	152

424	3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. *Journal of the American College of Cardiology*, **2017**, 70, 2852-2862	15.1	150
423	Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). *JACC: Cardiovascular Interventions*, **2013**, 6, 914-22	5	144
422	Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. *JACC: Cardiovascular Interventions*, **2009**, 2, 1269-75	5	143
421	Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. *European Heart Journal*, **2017**, 38, 3502-3510	9.5	141
420	Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation*, **2007**, 115, 2842-7	16.7	141
419	Natural History, Diagnostic Approaches, and Therapeutic Strategies for Patients With Asymptomatic Severe Aortic Stenosis. *Journal of the American College of Cardiology*, **2016**, 67, 2263-2288	15.1	139
418	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. *New England Journal of Medicine*, **2020**, 382, 1408-1419	59.2	138
417	Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *Journal of the American College of Cardiology*, **2009**, 54, 1477-84	15.1	138
416	Insights into echo-attenuated plaques, echolucent plaques, and plaques with spotty calcification: novel findings from comparisons among intravascular ultrasound, near-infrared spectroscopy, and pathological histology in 2,294 human coronary artery segments. *Journal of the American College of Cardiology*, **2014**, 63, 2220-33	15.1	136
415	Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. *Journal of the American College of Cardiology*, **2003**, 42, 1739-46	15.1	135
414	2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. *Lancet, The*, **2017**, 390, 760-772	40	133
413	The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?. *European Heart Journal*, **2015**, 36, 1651-9	9.5	133
412	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. *American Heart Journal*, **2018**, 201, 124-135	4.9	132
411	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. *Journal of the American College of Cardiology*, **2015**, 66, 278-307	15.1	128
410	Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. *Circulation*, **2018**, 138, 2216-2226	16.7	127
409	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. *Journal of the American College of Cardiology*, **2019**, 73, 741-754	15.1	123
408	Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. *Journal of the American College of Cardiology*, **2006**, 48, 32-6	15.1	123
407	Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. *Circulation: Cardiovascular Interventions*, **2012**, 5, 357-64	6	116

406	Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. *European Heart Journal*, **2017**, 38, 2201-2207	9.5	115
405	Periprocedural myocardial infarction: prevalence, prognosis, and prevention. *Circulation: Cardiovascular Interventions*, **2010**, 3, 602-10	6	114
404	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *New England Journal of Medicine*, **2020**, 382, 1208-1218	59.2	112
403	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. *European Heart Journal*, **2017**, 38, 1034-1043	9.5	110
402	Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. *European Heart Journal*, **2016**, 37, 3090-3095	9.5	110
401	Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. *Circulation*, **2018**, 137, 464-479	16.7	108
400	Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. *Circulation: Cardiovascular Interventions*, **2014**, 7, 285-93	6	108
399	Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention. *Circulation*, **2016**, 134, 422-31	16.7	108
398	Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention). *JACC: Cardiovascular Interventions*, **2015**, 8, 1704-14	5	106
397	Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. *American Journal of Cardiology*, **2007**, 100, 1370-5	3	105
396	Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials. *Journal of the American College of Cardiology*, **2017**, 70, 2863-2874	15.1	103
395	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. *Lancet, The*, **2013**, 382, 1879-88	40	102
394	Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *Journal of the American College of Cardiology*, **2005**, 45, 1180-5	15.1	102
393	Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *Circulation*, **2012**, 125, 2613-20	16.7	99
392	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002475	6	97
391	Do plaques rapidly progress prior to myocardial infarction? The interplay between plaque vulnerability and progression. *Circulation Research*, **2015**, 117, 99-104	15.7	95
390	A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. *JACC: Cardiovascular Interventions*, **2009**, 2, 428-34	5	94
389	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *European Heart Journal*, **2018**, 39, 2192-2207	9.5	91

388	Global position paper on cardiovascular regenerative medicine. *European Heart Journal*, **2017**, 38, 2532-2546	9.5	90
387	Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American College of Cardiology*, **2019**, 74, 2969-2979	15.1	88
386	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 77, 1903-1921	15.1	84
385	Bioresorbable Vascular Scaffolds for Coronary Revascularization. *Circulation*, **2016**, 134, 168-82	16.7	82
384	Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. *Circulation: Cardiovascular Interventions*, **2009**, 2, 366-75	6	80
383	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. *European Heart Journal*, **2015**, 36, 1231-41	9.5	79
382	The Primary Outcome Is Positive - Is That Good Enough?. *New England Journal of Medicine*, **2016**, 375, 971-9	59.2	78
381	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. *Journal of the American College of Cardiology*, **2017**, 69, 2011-2022	15.1	77
380	Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2016**, 387, 136-45	40	77
379	Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). *Journal of the American College of Cardiology*, **2014**, 63, 619-629	15.1	73
378	Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002837	6	71
377	Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials. *American Heart Journal*, **2017**, 185, 26-34	4.9	70
376	Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. *Journal of the American College of Cardiology*, **2016**, 67, 81-99	15.1	70
375	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. *Journal of the American College of Cardiology*, **2020**, 76, 2635-2646	15.1	70
374	Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events: The PROSPECT Study. *JACC: Cardiovascular Imaging*, **2018**, 11, 462-471	8.4	69
373	Association of Coronary Stenosis and Plaque Morphology With Fractional Flow Reserve and Outcomes. *JAMA Cardiology*, **2016**, 1, 350-7	16.2	69
372	Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention: The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow). *JACC: Cardiovascular Interventions*, **2015**, 8, 927-36	5	68
371	Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. *European Heart Journal*, **2018**, 39, 3574-3581	9.5	67

370	Fractional Flow Reserve/Instantaneous Wave-Free Ratio Discordance in Angiographically Intermediate Coronary Stenoses: An Analysis Using Doppler-Derived Coronary Flow Measurements. *JACC: Cardiovascular Interventions*, **2017**, 10, 2514-2524	5	66
369	Combined IVUS and NIRS detection of fibroatheromas: histopathological validation in human coronary arteries. *JACC: Cardiovascular Imaging*, **2015**, 8, 184-94	8.4	66
368	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. *JAMA Cardiology*, **2019**, 4, 273-286	16.2	65
367	New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. *Journal of the American College of Cardiology*, **2018**, 71, 739-748	15.1	65
366	Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention: The DEFINE PCI Study. *JACC: Cardiovascular Interventions*, **2019**, 12, 1991-2001	5	65
365	Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *American Journal of Cardiology*, **2005**, 96, 325-31	3	65
364	Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. *European Heart Journal*, **2020**, 41, 3228-3235	9.5	64
363	Reperfusion strategies in acute coronary syndromes. *Circulation Research*, **2014**, 114, 1918-28	15.7	64
362	Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. *American Heart Journal*, **2012**, 163, 768-776.e2	4.9	64
361	Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). *American Journal of Cardiology*, **2014**, 113, 236-42	3	63
360	Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. *Journal of the American College of Cardiology*, **2019**, 73, 2123-2132	15.1	61
359	Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. *Journal of the American College of Cardiology*, **2020**, 75, 590-604	15.1	61
358	5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. *JACC: Cardiovascular Interventions*, **2011**, 4, 300-9	5	57
357	Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). *Journal of the American College of Cardiology*, **2014**, 63, 15-20	15.1	56
356	Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. *Lancet, The*, **2017**, 390, 2655-2661	40	56
355	Intracoronary Optical Coherence Tomography 2018: Current Status and Future Directions. *JACC: Cardiovascular Interventions*, **2017**, 10, 2473-2487	5	56
354	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. *American Heart Journal*, **2018**, 205, 1-11	4.9	55
353	Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. *Circulation*, **2020**, 142, 841-857	16.7	54

352	Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. *Journal of the American College of Cardiology*, **2018**, 71, 591-602	15.1	54
351	3-Year Outcomes of the DKCRUSH-V Trial Comparing DK Crush With Provisional Stenting for Left Main Bifurcation Lesions. *JACC: Cardiovascular Interventions*, **2019**, 12, 1927-1937	5	52
350	Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients. *European Heart Journal*, **2017**, 38, 3160-3172	9.5	51
349	Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. *EuroIntervention*, **2016**, 12, 861-72	3.1	51
348	Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *Catheterization and Cardiovascular Interventions*, **2014**, 83, 27-36	2.7	50
347	Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. *JACC: Cardiovascular Interventions*, **2011**, 4, 530-42	5	50
346	Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial. *Circulation: Cardiovascular Interventions*, **2014**, 7, 543-51	6	49
345	Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 159-166	4.1	48
344	Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. *JAMA Cardiology*, **2019**, 4, 1261-1269	16.2	48
343	Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. *Journal of the American College of Cardiology*, **2020**, 76, 2289-2301	15.1	48
342	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. *Circulation*, **2020**, 142, 1425-1436	16.7	48
341	Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. *Circulation: Cardiovascular Interventions*, **2015**, 8, e001683	6	47
340	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. *Circulation*, **2016**, 133, 39-47	16.7	46
339	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. *International Journal of Cardiology*, **2017**, 231, 61-67	3.2	45
338	Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. *Lancet, The*, **2021**, 397, 985-995	40	45
337	Survival After Varying Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: A Pairwise and Network Meta-Analysis. *JACC: Cardiovascular Interventions*, **2016**, 9, 1765-76	5	45
336	Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial). *American Journal of Cardiology*, **2015**, 115, 1685-90	3	43
335	Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. *European Heart Journal*, **2020**, 41, 2523-2536	9.5	43

334	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease: The EXCEL Trial. *JACC: Cardiovascular Interventions*, **2018**, 11, 1234-1243	5	42
333	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial. *Journal of the American College of Cardiology*, **2017**, 70, 3113-3122	15.1	41
332	Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. *Journal of the American Heart Association*, **2016**, 5,	6	41
331	Impact of positive and negative lesion site remodeling on clinical outcomes: insights from PROSPECT. *JACC: Cardiovascular Imaging*, **2014**, 7, 70-8	8.4	41
330	Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). *JACC: Cardiovascular Interventions*, **2015**, 8, 1966-1974	5	41
329	Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. *European Heart Journal*, **2019**, 40, 1930-1941	9.5	40
328	Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. *Trends in Pharmacological Sciences*, **2015**, 36, 605-16	13.2	40
327	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. *Journal of the American College of Cardiology*, **2018**, 72, 754-765	15.1	39
326	Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. *JACC: Cardiovascular Interventions*, **2013**, 6, 36-43	5	39
325	Clinical outcome of nonculprit plaque ruptures in patients with acute coronary syndrome in the PROSPECT study. *JACC: Cardiovascular Imaging*, **2014**, 7, 397-405	8.4	39
324	Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. *Canadian Journal of Cardiology*, **2016**, 32, 226-33	3.8	38
323	Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). *JACC: Cardiovascular Interventions*, **2014**, 7, 733-40	5	38
322	Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. *Journal of the American College of Cardiology*, **2015**, 66, 2757-2766	15.1	38
321	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. *Journal of the American College of Cardiology*, **2019**, 73, 1616-1628	15.1	37
320	Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). *American Journal of Cardiology*, **2014**, 114, 1823-9	3	37
319	Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. *Circulation*, **2008**, 118, 538-51	16.7	37
318	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. *Journal of the American College of Cardiology*, **2021**, 77, 1029-1040	15.1	36
317	Comparison of plaque characteristics in narrowings with ST-elevation myocardial infarction (STEMI), non-STEMI/unstable angina pectoris and stable coronary artery disease (from the ADAPT-DES IVUS Substudy). *American Journal of Cardiology*, **2015**, 115, 860-6	3	35

316	Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *American Journal of Cardiology*, **2011**, 108, 1068-74	3	35
315	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. *JACC: Cardiovascular Interventions*, **2016**, 9, 674-84	5	35
314	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. *Journal of the American College of Cardiology*, **2017**, 70, 1846-1857	15.1	34
313	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. *Circulation: Cardiovascular Interventions*, **2015**, 8,	6	34
312	Vulnerable plaques and patients: state-of-the-art. *European Heart Journal*, **2020**, 41, 2997-3004	9.5	34
311	Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). *JACC: Cardiovascular Interventions*, **2014**, 7, 372-9	5	34
310	Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention. *JACC: Cardiovascular Imaging*, **2012**, 5, S76-85	8.4	34
309	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. *Circulation*, **2021**, 143, 479-500	16.7	34
308	Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials. *International Journal of Cardiology*, **2017**, 244, 121-127	3.2	33
307	Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial. *Circulation*, **2019**, 140, 1895-1903	16.7	33
306	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). *JACC: Cardiovascular Interventions*, **2016**, 9, 207-215	5	33
305	Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. *American Heart Journal*, **2015**, 170, 641-651.e3	4.9	33
304	Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. *Journal of the American College of Cardiology*, **2015**, 66, 2886-2898	15.1	33
303	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. *New England Journal of Medicine*, **2020**, 382, 1619-1628	59.2	32
302	Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). *American Journal of Cardiology*, **2014**, 113, 1457-60	3	32
301	Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). *Circulation*, **2017**, 136, 1304-1314	16.7	32
300	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. *European Heart Journal*, **2018**, 39, 4112-4121	9.5	32
299	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. *JAMA Cardiology*, **2017**, 2, 127-135	16.2	30

298	Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis. *Medical Science Monitor Basic Research*, **2017**, 23, 179-222	3.2	30
297	Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2019**, 74, 2102-2112	15.1	30
296	Accuracy of Fractional Flow Reserve Measurements in Clinical Practice: Observations From a Core Laboratory Analysis. *JACC: Cardiovascular Interventions*, **2017**, 10, 1392-1401	5	30
295	Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis. *Kardiologia Polska*, **2018**, 76, 107-118	0.9	30
294	Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). *American Journal of Cardiology*, **2014**, 114, 9-16	3	29
293	Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. *Circulation: Cardiovascular Interventions*, **2012**, 5, 150-6	6	29
292	Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial. *Journal of the American College of Cardiology*, **2016**, 67, 2249-2258	15.1	29
291	Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. *Journal of the American College of Cardiology*, **2020**, 75, 1631-1640	15.1	28
290	Prevalence and Clinical Impact of Tissue Protrusion After Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy. *JACC: Cardiovascular Interventions*, **2016**, 9, 1499-507	5	28
289	Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Secondary Mitral Regurgitation. *Journal of the American College of Cardiology*, **2020**, 75, 750-758	15.1	27
288	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. *JACC: Cardiovascular Interventions*, **2016**, 9, 1905-13	5	27
287	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. *American Heart Journal*, **2018**, 205, 42-52	4.9	27
286	Angioplasty strategies in ST-segment-elevation myocardial infarction: part II: intervention after fibrinolytic therapy, integrated treatment recommendations, and future directions. *Circulation*, **2008**, 118, 552-66	16.7	27
285	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. *Circulation*, **2020**, 142, 1725-1735	16.7	27
284	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction Trials). *American Journal of Cardiology*, **2017**, 119, 1710-1716	3	26
283	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. *American Journal of Cardiology*, **2015**, 116, 845-52	3	26
282	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial. *JACC: Cardiovascular Interventions*, **2020**, 13, 375-387	5	26
281	Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients. *JACC: Cardiovascular Interventions*, **2018**, 11, 892-902	5	26

280	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. *Journal of the American College of Cardiology*, **2020**, 76, 1609-1621	15.1	26
279	Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. *Journal of the American College of Cardiology*, **2020**, 76, 1521-1531	15.1	25
278	International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. *Journal of the American College of Cardiology*, **2021**, 77, 2466-2476	15.1	25
277	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. *American Heart Journal*, **2019**, 214, 134-141	4.9	24
276	Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease: Anatomy, Physiology, or Morphology?. *Circulation Research*, **2016**, 119, 317-29	15.7	24
275	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. *JACC: Cardiovascular Interventions*, **2016**, 9, 28-38	5	24
274	Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. *American Journal of Cardiology*, **2016**, 117, 1877-83	3	24
273	Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention. *Circulation: Cardiovascular Interventions*, **2018**, 11, e007007	6	24
272	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JACC: Cardiovascular Interventions*, **2016**, 9, 1890-901	5	23
271	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. *Circulation*, **2016**, 133, 248-55	16.7	23
270	Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). *American Journal of Cardiology*, **2014**, 113, 36-43	3	23
269	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). *Circulation*, **2016**, 134, 723-33	16.7	23
268	Percutaneous Coronary Intervention of Saphenous Vein Graft. *Circulation: Cardiovascular Interventions*, **2017**, 10,	6	22
267	Usefulness of the troponin-ejection fraction product to differentiate stress cardiomyopathy from ST-segment elevation myocardial infarction. *American Journal of Cardiology*, **2014**, 113, 429-33	3	22
266	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). *JACC: Cardiovascular Interventions*, **2015**, 8, 1978-1987	5	22
265	Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. *Circulation: Cardiovascular Interventions*, **2018**, 11, e006243	6	22
264	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. *American Heart Journal*, **2017**, 190, 135-139	4.9	21
263	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. *Journal of the American College of Cardiology*, **2019**, 73, 1877-1886	15.1	21

262	Pressure-controlled intermittent coronary sinus occlusion (PICSO) in acute ST-segment elevation myocardial infarction: results of the Prepare RAMSES safety and feasibility study. *EuroIntervention*, **2015**, 11, 37-44	3.1	21
261	Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. *Circulation*, **2021**, 143, 790-804	16.7	21
260	Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. *Nature Reviews Cardiology*, **2021**, 18, 155-168	14.8	21
259	Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 840-853	15.1	21
258	Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. *JACC: Cardiovascular Interventions*, **2020**, 13, 1417-1428	5	20
257	A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. *JACC: Cardiovascular Interventions*, **2018**, 11, 260-272	5	20
256	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. *Journal of the American College of Cardiology*, **2016**, 67, 596-8	15.1	20
255	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. *JACC: Cardiovascular Interventions*, **2017**, 10, 1809-1815	5	20
254	Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial. *Journal of the American College of Cardiology*, **2020**, 76, 1305-1314	15.1	20
253	Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. *American Journal of Cardiology*, **2018**, 121, 529-536	3	19
252	Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial. *Catheterization and Cardiovascular Interventions*, **2016**, 88, 369-77	2.7	19
251	Management of left main disease: an update. *European Heart Journal*, **2019**, 40, 1454-1466	9.5	19
250	Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). *American Journal of Cardiology*, **2017**, 119, 1295-1301	3	18
249	Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial. *American Heart Journal*, **2020**, 223, 72-80	4.9	18
248	Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. *Journal of the American College of Cardiology*, **2020**, 75, 1743-1754	15.1	18
247	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. *JACC: Cardiovascular Interventions*, **2018**, 11, 68-76	5	18
246	Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trials). *American Journal of Cardiology*, **2014**, 113, 930-5	3	18
245	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JAMA Cardiology*, **2017**, 2, 855-862	16.2	18

244	Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with non-ST-segment-elevation acute coronary syndrome: analysis from the Acute Catheterization and Early Intervention Triage Strategy trial. *Circulation: Cardiovascular Interventions*, **2015**, 8,	6	18
243	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. *Journal of the American College of Cardiology*, **2019**, 74, 2572-2584	15.1	18
242	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). *Circulation: Cardiovascular Interventions*, **2017**, 10,	6	17
241	Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy. *JACC: Cardiovascular Interventions*, **2017**, 10, 42-49	5	17
240	Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials. *American Heart Journal*, **2019**, 213, 105-111	4.9	17
239	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. *European Heart Journal*, **2020**, 41, 2799-2810	9.5	17
238	Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents. *Journal of Interventional Cardiology*, **2013**, 26, 49-57	1.8	17
237	Ex vivo validation of 45 MHz intravascular ultrasound backscatter tissue characterization. *European Heart Journal Cardiovascular Imaging*, **2015**, 16, 1112-9	4.1	17
236	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. *Lancet, The*, **2021**,	40	17
235	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. *Circulation: Cardiovascular Interventions*, **2020**, 13, e009565	6	17
234	Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. *European Heart Journal*, **2021**, 42, 2643-2654	9.5	17
233	Prognostic Impact of Race in Patients Undergoing PCI: Analysis From 10 Randomized Coronary Stent Trials. *JACC: Cardiovascular Interventions*, **2020**, 13, 1586-1595	5	16
232	Algorithmic Approach for Optical Coherence Tomography-Guided Stent Implantation During Percutaneous Coronary Intervention. *Interventional Cardiology Clinics*, **2018**, 7, 329-344	1.4	16
231	Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. *Medical Science Monitor Basic Research*, **2017** , 23, 58-86	3.2	16
230	Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. *Lancet, The*, **2021**,	40	16
229	The win ratio approach for composite endpoints: practical guidance based on previous experience. *European Heart Journal*, **2020**, 41, 4391-4399	9.5	16
228	Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study). *American Journal of Cardiology*, **2017**, 119, 1917-1923	3	15
227	Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. *JACC: Cardiovascular Interventions*, **2019**, 12, 805-819	5	15

226	Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents. *Circulation: Cardiovascular Interventions*, **2015**, 8,	6	15
225	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: COAPT Trial. *Journal of the American College of Cardiology*, **2020**, 75, 2099-2106	15.1	15
224	Trends in Usage and Clinical Outcomes of Coronary Atherectomy: A Report From the National Cardiovascular Data Registry CathPCI Registry. *Circulation: Cardiovascular Interventions*, **2020**, 13, e008239	6	15
223	Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis. *American Heart Journal*, **2018**, 195, 78-85	4.9	15
222	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. *Circulation*, **2021**, 144, 1024-1038	16.7	15
221	Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results. *JACC: Cardiovascular Interventions*, **2018**, 11, 638-644	5	14
220	Ticagrelor in ACS: redefining a new standard of care?. *Lancet, The*, **2010**, 375, 263-5	40	14
219	Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. *JAMA Cardiology*, **2021**, 6, 427-436	16.2	14
218	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. *American Journal of Cardiology*, **2016**, 117, 1703-13	3	14
217	Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). *American Journal of Cardiology*, **2016**, 118, 1097-1104	3	14
216	Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e006002	5.8	14
215	Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction: The IC-HOT study. *Catheterization and Cardiovascular Interventions*, **2019**, 93, 882-890	2.7	14
214	Heterogeneity of Plaque Structural Stress Is Increased in Plaques Leading to MACE: Insights From the PROSPECT Study. *JACC: Cardiovascular Imaging*, **2020**, 13, 1206-1218	8.4	14
213	Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. *Circulation: Cardiovascular Interventions*, **2019**, 12, e007541	6	13
212	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. *JACC: Cardiovascular Interventions*, **2018**, 11, 53-65	5	13
211	Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. *Clinical Research in Cardiology*, **2017**, 106, 165-173	6.1	13
210	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence?. *Circulation*, **2017**, 135, 819-821	16.7	12
209	Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). *American Journal of Cardiology*, **2015**, 116, 1658-65	3	12

208	Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program. *JAMA Cardiology*, **2019**, 4, 727-735	16.2	12
207	Intravascular Ultrasound and Near-Infrared Spectroscopic Characterization of Thin-Cap Fibroatheroma. *American Journal of Cardiology*, **2017**, 119, 372-378	3	12
206	Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: insights from the DESERT cooperation. *International Journal of Cardiology*, **2014**, 175, 50-4	3.2	12
205	Ischaemia versus bleeding: the art of clinical decision-making. *Lancet, The*, **2009**, 373, 695-6	40	12
204	Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years. *JACC: Cardiovascular Interventions*, **2020**, 13, 116-127	5	12
203	The Hybrid Coronary Approach for Optimal Revascularization: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2020**, 76, 321-333	15.1	12
202	Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy: The COAPT Trial. *Circulation: Heart Failure*, **2020**, 13, e007293	7.6	12
201	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. *Circulation*, **2021**, 144, 426-437	16.7	12
200	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. *Journal of the American College of Cardiology*, **2017**, 69, 2304-2313	15.1	11
199	Association of measured platelet reactivity with changes in P2Y receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. *American Heart Journal*, **2017**, 187, 19-28	4.9	11
198	Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). *American Heart Journal*, **2015**, 169, 86-93	4.9	11
197	Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial. *American Heart Journal*, **2020**, 225, 10-18	4.9	11
196	Cardiovascular and Noncardiovascular Death After Percutaneous Coronary Intervention: Insights From 32 882 Patients Enrolled in 21 Randomized Trials. *Circulation: Cardiovascular Interventions*, **2018**, 11, e006488	6	11
195	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. *International Journal of Cardiology*, **2017**, 246, 20-25	3.2	11
194	Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. *Catheterization and Cardiovascular Interventions*, **2017**, 89, 178-189	2.7	11
193	Shear Stress Estimated by Quantitative Coronary Angiography Predicts Plaques Prone to Progress and Cause Events. *JACC: Cardiovascular Imaging*, **2020**, 13, 2206-2219	8.4	11
192	NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: The COAPT Trial. *JACC: Cardiovascular Interventions*, **2020**, 13, 2317-2328	5	11
191	Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions: Patient-Level Pooled Analysis of the Disrupt CAD Studies. *JACC: Cardiovascular Interventions*, **2021**, 14, 1337-1348	5	11

190	Effect of Functional Mitral Regurgitation on Outcome in Patients Receiving Cardiac Resynchronization Therapy for Heart Failure. *American Journal of Cardiology*, **2019**, 123, 75-83	3	11
189	Age-related effects of smoking on coronary artery disease assessed by gray scale and virtual histology intravascular ultrasound. *American Journal of Cardiology*, **2015**, 115, 1056-62	3	10
188	Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy. *JACC: Cardiovascular Imaging*, **2016**, 9, 849-854	8.4	10
187	Novel 3-Dimensional Vessel and Scaffold Reconstruction Methodology for the Assessment of Strut-Level Wall Shear Stress After Deployment of Bioresorbable Vascular Scaffolds From the ABSORB III Imaging Substudy. *JACC: Cardiovascular Interventions*, **2016**, 9, 501-3	5	10
186	Comparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). *American Journal of Cardiology*, **2014**, 113, 1273-9	3	10
185	Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American College of Cardiology*, **2020**, 76, 1007-1014	15.1	10
184	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. *JACC: Cardiovascular Interventions*, **2020**, 13, 2331-2341	5	10
183	Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. *Journal of the American College of Cardiology*, **2021**, 78, 348-361	15.1	10
182	Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trial *European Journal of Cardio-thoracic Surgery*, **2019**, 55, 501-510	3	10
181	Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials. *American Heart Journal*, **2017**, 188, 18-25	4.9	9
180	Bioprosthetic surgical and transcatheter heart valve thrombosis. *Lancet, The*, **2017**, 389, 2352-2354	40	9
179	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). *Circulation: Cardiovascular Intervention*, **2018**, 11, e005625	6	9
178	Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). *American Journal of Cardiology*, **2018**, 121, 678-683	3	9
177	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. *Circulation: Cardiovascular Interventions*, **2016**, 9,	6	9
176	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. *Circulation: Cardiovascular Interventions*, **2016**, 9, e002995	6	9
175	Impact of multiple complex plaques on short- and long-term clinical outcomes in patients presenting with ST-segment elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). *American Journal of Cardiology*, **2014**, 113, 1191-7	3	9
174	Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials. *JACC: Cardiovascular Interventions*, **2017**, 10, 1881-1890	5	9
173	Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002447	6	9

172	Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI. *American Heart Journal*, **2015**, 169, 242-8	4.9	9
171	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 1635-1654	15.1	9
170	Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American College of Cardiology*, **2020**, 76, 2595-2606	15.1	9
169	Percutaneous coronary intervention or coronary artery bypass graft in left main coronary artery disease: a comprehensive meta-analysis of adjusted observational studies and randomized controlled trials. *Journal of Cardiovascular Medicine*, **2018**, 19, 554-563	1.9	9
168	Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction. *European Heart Journal*, **2016**, 37, 484-93	9.5	8
167	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Disease. *New England Journal of Medicine*, **2017**, 376, 1089	59.2	8
166	Bleeding Severity After Percutaneous Coronary Intervention. *Circulation: Cardiovascular Interventions*, **2018**, 11, e005542	6	8
165	Off-Pump Versus On-Pump Bypass Surgery for Left Main Coronary Artery Disease. *Journal of the American College of Cardiology*, **2019**, 74, 729-740	15.1	8
164	Does calcium burden impact culprit lesion morphology and clinical results? An ADAPT-DES IVUS substudy. *International Journal of Cardiology*, **2017**, 248, 97-102	3.2	8
163	Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. *Cardiovascular Revascularization Medicine*, **2014**, 15, 375-80	1.6	8
162	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. *Thrombosis and Haemostasis*, **2020**, 120, 348-362	7	8
161	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. *Circulation: Cardiovascular Interventions*, **2016**, 9, e003272	6	8
160	Optical coherence tomography in coronary atherosclerosis assessment and intervention.. *Nature Reviews Cardiology*, **2022**,	14.8	8
159	Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document. *JACC: Cardiovascular Interventions*, **2018**, 11, 823-832	5	7
158	Imaging-guided pre-dilatation, stenting, post-dilatation: a protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 431-440	2.5	7
157	Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. *American Heart Journal*, **2014**, 167, 43-50	4.9	7
156	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. *Circulation: Cardiovascular Interventions*, **2021**, 14, e010300	6	7
155	Limitations of Repeat Revascularization as an Outcome Measure: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2019**, 74, 3164-3173	15.1	7

154	One-year outcomes of supersaturated oxygen therapy in acute anterior myocardial infarction: The IC-HOT study. *Catheterization and Cardiovascular Interventions*, **2021**, 97, 1120-1126	2.7	7
153	Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. *Circulation: Cardiovascular Interventions*, **2021**, 14, e009879	6	7
152	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. *Circulation: Cardiovascular Interventions*, **2017**, 10,	6	6
151	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. *International Journal of Cardiology*, **2018**, 263, 24-28	3.2	6
150	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. *European Heart Journal: Acute Cardiovascular Care*, **2018**, 7, 158-165	4.3	6
149	Optimum technique to reduce risk of stent thrombosis - Authors' reply. *Lancet, The*, **2016**, 388, 127-8	40	6
148	Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). *American Journal of Cardiology*, **2014**, 114, 1638-45	3	6
147	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. *Circulation: Cardiovascular Interventions*, **2017**, 10,	6	6
146	Clinical Endpoints and Key Data Elements in Percutaneous Coronary Intervention of Coronary Chronic Total Occlusion Studies: A Call to the Academic Research Consortium for Standardized Definitions. *JACC: Cardiovascular Interventions*, **2017**, 10, 2185-2187	5	6
145	Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. *Catheterization and Cardiovascular Interventions*, **2000**, 51, 131-7	2.7	6
144	1-Year Outcomes of Blinded Physiological Assessment of Residual Ischemia After Successful PCI: DEFINE PCI Trial.. *JACC: Cardiovascular Interventions*, **2022**, 15, 52-61	5	6
143	Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysis From the COAPT Trial. *JACC: Cardiovascular Interventions*, **2021**, 14, 2231-2242	5	6
142	Novel Micro Crown Orbital Atherectomy for Severe Lesion Calcification: Coronary Orbital Atherectomy System Study (COAST). *Circulation: Cardiovascular Interventions*, **2020**, 13, e008993	6	6
141	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. *Mayo Clinic Proceedings*, **2016**, 91, 1413-1447	6.4	6
140	Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 931-956	15.1	6
139	Bleeding associated with the management of acute coronary syndromes. *Heart*, **2017**, 103, 546-562	5.1	5
138	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). *Circulation: Cardiovascular Interventions*, **2017**, 10,	6	5
137	Interventional Management of Unprotected Left Main Coronary Artery Disease: Patient Selection and Technique Optimization. *Journal of Interventional Cardiology*, **2015**, 28, 326-38	1.8	5

136	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. *Catheterization and Cardiovascular Interventions*, **2018**, 92, E348-E355	2.7	5
135	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. *American Journal of Cardiology*, **2016**, 118, 1661-1668	3	5
134	Utility of near-infrared spectroscopy for detection of thin-cap neoatherosclerosis. *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 663-669	4.1	5
133	"Optimized" delivery of intracoronary supersaturated oxygen in acute anterior myocardial infarction: a feasibility and safety study. *Catheterization and Cardiovascular Interventions*, **2015**, 86 Suppl 1, S51-7	2.7	5
132	Antithrombin alternatives in STEMI. *Lancet, The*, **2011**, 378, 643-5	40	5
131	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation: Results From the COAPT Trial. *JACC: Cardiovascular Interventions*, **2021**, 14, 879-889	5	5
130	Considerations for an optimal definition of procedural myocardial infarction. *European Heart Journal*, **2020**, 41, 1704-1705	9.5	5
129	Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications. *Heart*, **2020**,	5.1	5
128	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. *Circulation*, **2021**, 144, 1380-1395	16.7	5
127	Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. *JACC: Heart Failure*, **2021**, 9, 674-683	7.9	5
126	Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. *European Heart Journal: Acute Cardiovascular Care*, **2017**, 6, 650-658	4.3	4
125	Secondary Mitral Regurgitation: Is it Time for a Paradigm Shift in Treatment?. *JACC: Heart Failure*, **2019**, 7, 522-526	7.9	4
124	Safety and feasibility evaluation of planning and execution of surgical revascularisation solely based on coronary CTA and FFR in patients with complex coronary artery disease: study protocol of the FASTTRACK CABG study. *BMJ Open*, **2020**, 10, e038152	3	4
123	Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. *American Heart Journal*, **2018**, 197, 142-149	4.9	4
122	Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. *International Journal of Cardiology*, **2018**, 250, 49-55	3.2	4
121	Completeness of revascularization and its impact on the outcomes of a staged approach of percutaneous coronary intervention followed by minimally invasive valve surgery for patients with concomitant coronary artery and valvular heart disease. *Catheterization and Cardiovascular Interventions*, **2016**, 88, 329-37	2.7	4
120	Impact of atrial fibrillation on improvement of functional mitral regurgitation in cardiac resynchronization therapy. *Heart Rhythm*, **2018**, 15, 1816-1822	6.7	4
119	ISCHEMIA: Establishing the Primary End Point. *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e004791	5.8	4

118	Acute coronary syndromes: finding meaning in OASIS 7. *Lancet, The*, **2010**, 376, 1203-5	40	4
117	Improved Short-Term Outcomes of Primary Coronary Stenting Compared to Primary Balloon Angioplasty in Acute Myocardial Infarction at Experienced Centers: The PAMI Study Group Experience. *Journal of Interventional Cardiology*, **1999**, 12, 101-108	1.8	4
116	Bioresorbable vascular scaffolds: is imaging everything?. *EuroIntervention*, **2014**, 9, 1255-7	3.1	4
115	Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial. *American Heart Journal*, **2020**, 228, 8-16	4.9	4
114	Standardizing the Definition and Analysis Methodology for Complete Coronary Artery Revascularization. *Journal of the American Heart Association*, **2021**, 10, e020110	6	4
113	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. *American Journal of Cardiology*, **2016**, 118, 6-16	3	4
112	External elastic lamina vs. luminal diameter measurement for determining stent diameter by optical coherence tomography: an ILUMIEN III substudy. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 753-759	4.1	4
111	Regurgitant Volume/Left Ventricular End-Diastolic Volume Ratio: Prognostic Value in Patients With Secondary Mitral Regurgitation. *JACC: Cardiovascular Imaging*, **2021**, 14, 730-739	8.4	4
110	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES. *JACC: Cardiovascular Interventions*, **2021**, 14, 417-427	5	4
109	Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial. *JACC: Cardiovascular Interventions*, **2017**, 10, 774-782	5	3
108	Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery for Multivessel Coronary Artery Disease: Toward Patient-Centric Decision Making. *JAMA Cardiology*, **2019**, 4, 507-508	16.2	3
107	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. *International Journal of Cardiology*, **2019**, 287, 59-61	3.2	3
106	Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. *Catheterization and Cardiovascular Interventions*, **2020**, 96, 1240-1248	2.7	3
105	Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals. *JAMA Network Open*, **2020**, 3, e203082	10.4	3
104	Predictors of Left Ventricular Remodeling After Myocardial Infarction in Patients With a Patent Infarct Related Coronary Artery After Percutaneous Coronary Intervention (from the Post-Myocardial Infarction Remodeling Prevention Therapy [PRomPT] Trial). *American Journal of Cardiology*, **2018**, 121, 1293-1298	3	3
103	Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials. *Catheterization and Cardiovascular Interventions*, **2018**, 91, 387-395	2.7	3
102	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. *Circulation: Cardiovascular Interventions*, **2019**, 12, e007734	6	3
101	Relation Between Renal Function and Coronary Plaque Morphology (from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Virtual Histology-Intravascular Ultrasound Substudy). *American Journal of Cardiology*, **2017**, 119, 217-224	3	3

100	Cost implications of intraprocedural thrombotic events during PCI. *Catheterization and Cardiovascular Interventions*, **2015**, 86, 30-9	2.7	3
99	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation.. *Heart*, **2022**,	5.1	3
98	BMI, Infarct Size, and Clinical Outcomes Following Primary PCI: Patient-Level Analysis From 6 Randomized Trials. *JACC: Cardiovascular Interventions*, **2020**, 13, 965-972	5	3
97	Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation: The COAPT Trial. *JACC: Cardiovascular Interventions*, **2020**, 13, 2795-2803	5	3
96	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. *Circulation: Heart Failure*, **2021**, 14, e007564	7.6	3
95	Therapeutic Approach to Calcified Coronary Lesions: Disruptive Technologies. *Current Cardiology Reports*, **2021**, 23, 33	4.2	3
94	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. *International Journal of Cardiology*, **2019**, 278, 217-222	3.2	3
93	Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry. *Catheterization and Cardiovascular Interventions*, **2021**, 97, 1162-1173	2.7	3
92	Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. *Cardiovascular Diabetology*, **2021**, 20, 10	8.7	3
91	Stent Expansion Indexes to Predict Clinical Outcomes: An IVUS Substudy From ADAPT-DES. *JACC: Cardiovascular Interventions*, **2021**, 14, 1639-1650	5	3
90	Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI. *JACC: Cardiovascular Interventions*, **2021**, 14, 1623-1634	5	3
89	Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. *JACC: Heart Failure*, **2021**, 9, 684-692	7.9	3
88	Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.. *Journal of the American College of Cardiology*, **2022**, 79, 917-928	15.1	3
87	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. *Circulation*, **2022**, 145, 847-863	16.7	3
86	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy.. *JACC: Cardiovascular Interventions*, **2022**,	5	3
85	Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. *American Journal of Cardiology*, **2019**, 123, 1399-1405	3	2
84	The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. *Journal of Cardiac Failure*, **2015**, 21, 601-7	3.3	2
83	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. *Clinical Cardiology*, **2019**, 42, 797	3.3	2

82	Impact of pre-procedural cardiopulmonary instability in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). *American Journal of Cardiology*, **2014**, 114, 962-7	3	2
81	Response to Letter Regarding Article, Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease: The Siegburg First-in-Man Study *Circulation*, **2007**, 115,	16.7	2
80	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: 1-Year Results From the Disrupt CAD III Study **2022**, 1, 100001		2
79	Update on Cardioprotective Strategies for STEMI: Focus on Supersaturated Oxygen Delivery.. *JACC Basic To Translational Science*, **2021**, 6, 1021-1033	8.7	2
78	Adverse events beyond 1 year after percutaneous coronary intervention. *Current Opinion in Cardiology*, **2020**, 35, 687-696	2.1	2
77	Percutaneous Coronary Intervention or Surgery for Unprotected Left Main Disease: EXCEL Trial at 5 Years. *Interventional Cardiology Clinics*, **2020**, 9, 419-432	1.4	2
76	The Nature of the P Value. *New England Journal of Medicine*, **2016**, 375, 2205-2206	59.2	2
75	Update on Intracoronary Optical Coherence Tomography: a Review of Current Concepts. *Current Cardiovascular Imaging Reports*, **2016**, 9, 1	0.7	2
74	Ultra-low-contrast angiography in patients with advanced chronic kidney disease and previous coronary artery bypass surgery. *Coronary Artery Disease*, **2019**, 30, 346-351	1.4	2
73	Absorb bioresorbable vascular scaffold outcomes following implantation with routine intravascular imaging guidance. *Catheterization and Cardiovascular Interventions*, **2021**, 97, 48-55	2.7	2
72	Reporting data from meta-analysis: snapshot of a moving target. *European Heart Journal*, **2021**,	9.5	2
71	Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.. *Circulation*, **2022**,	16.7	2
70	Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. *Circulation: Cardiovascular Interventions*, **2015**, 8,	6	1
69	Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization. *Journal of the American College of Cardiology*, **2020**, 75, 1493-1495	15.1	1
68	Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. *American Journal of Cardiology*, **2020**, 127, 16-24	3	1
67	Acute coronary syndromes in 2013: Optimizing revascularization strategies in patients with ACS. *Nature Reviews Cardiology*, **2014**, 11, 67-8	14.8	1
66	The next 10 years in interventional cardiology. Interview by Louise Rishton. *Expert Review of Cardiovascular Therapy*, **2013**, 11, 537-40	2.5	1
65	Age-Related Outcomes After Transcatheter Mitral Valve Repair in Patients With Heart Failure: Analysis From COAPT.. *JACC: Cardiovascular Interventions*, **2022**, 15, 397-397	5	1

64	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies **2022**, 1, 100011		1
63	Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.. *European Heart Journal*, **2022**,	9.5	1
62	Magnetically-controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-induced Gastrointestinal Injury. *Journal of the American College of Cardiology*, **2021**,	15.1	1
61	Intralesional delivery of glycoprotein IIb/IIIa inhibitors in acute myocardial infarction: Review and recommendations. *Catheterization and Cardiovascular Interventions*, **2021**,	2.7	1
60	Treatment of mitral regurgitation: cut, clip or medicate?. *EuroIntervention*, **2019**, 14, 1710-1712	3.1	1
59	The five Ws of transcatheter mitral valve repair: Who, What, When, Where, and Why. *EuroIntervention*, **2019**, 15, 837-840	3.1	1
58	How should procedure-related myocardial infarction be defined, and does it matter? (Spoiler alert - it does!). *EuroIntervention*, **2020**, 15, 1393-1396	3.1	1
57	Extramitral Valvular Cardiac Involvement in Patients With Significant Secondary Mitral Regurgitation. *American Journal of Cardiology*, **2021**,	3	1
56	Percutaneous Coronary Intervention Followed by Minimally Invasive Mitral Valve Surgery in Ischemic Mitral Regurgitation. *Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery*, **2015**, 10, 394-397	1.5	1
55	Comparison of Age (. *American Journal of Cardiology*, **2020**, 125, 685-693	3	1
54	Incidence and Prognostic Impact of Atrial Fibrillation After Discharge Following Revascularization for Significant Left Main Coronary Artery Narrowing. *American Journal of Cardiology*, **2020**, 125, 500-506	3	1
53	Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". *Circulation*, **2021**, 143, e795-e796	16.7	1
52	Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction. *European Heart Journal: Acute Cardiovascular Care*, **2021**, 10, 687-697	4.3	1
51	Impact of Coronary Artery Tortuosity on Outcomes Following Stenting: A Pooled Analysis From 6 Trials. *JACC: Cardiovascular Interventions*, **2021**, 14, 1009-1018	5	1
50	Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry.. *Structural Heart*, **2021**, 5, 424-426	0.6	1
49	Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. *American Journal of Cardiovascular Drugs*, **2021**, 1	4	1
48	""-spontaneous coronary artery dissection and the potential of bioresorbable scaffolds. *Journal of Thoracic Disease*, **2016**, 8, E1398-E1403	2.6	1
47	Letter by Azzalini and Stone Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial". *Circulation: Cardiovascular Interventions*, **2020**, 13, e009140	6	1

46	Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 827-839	15.1	1
45	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. *Minerva Cardiology and Angiology*, **2021**, 69, 398-407	2.4	1
44	Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. *Journal of Cardiology*, **2021**, 78, 224-229	3	1
43	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial.. *Journal of the American College of Cardiology*, **2022**, 79, 651-661	15.1	1
42	Outcomes of Quantitative Flow Ratio-Based Percutaneous Coronary Intervention in an All-Comers Study. *EuroIntervention*, **2021**,	3.1	1
41	PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes **2022**, 1, 100020		1
40	Response to Letters re: The COAPT Trial. *Cardiovascular Revascularization Medicine*, **2019**, 20, 531-532	1.6	0
39	Cellular and molecular approaches to enhance myocardial recovery after myocardial infarction. *Cardiovascular Revascularization Medicine*, **2019**, 20, 351-364	1.6	0
38	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. *Circulation: Cardiovascular Interventions*, **2021**, CIRCINTERVENTIONS120010390	6	0
37	Who and when to clip: that is the question. *European Journal of Heart Failure*, **2020**, 22, 20-22	12.3	0
36	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. *Journal of the American College of Cardiology*, **2021**, 78, 1968-1986	15.1	0
35	The Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization: Rationale and Design of the PRECISE Trial.. *American Heart Journal*, **2021**, 245, 136-136	4.9	0
34	Device profile of the MobiusHD EVBA system for the treatment of resistant hypertension: overview of its mechanism of action, safety and efficacy. *Expert Review of Medical Devices*, **2020**, 17, 649-658	3.5	0
33	Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease. *Coronary Artery Disease*, **2022**, 31, 37-44	1.4	0
32	Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug-eluting stents. *Catheterization and Cardiovascular Interventions*, **2021**, 98, 723-732	2.7	0
31	Incidence and Predictors of Target Lesion Failure in Patients With Lesions in Small Vessels Undergoing PCI With Contemporary Drug-Eluting Stents: Insights From the BIONICS Study. *Cardiovascular Revascularization Medicine*, **2021**, 25, 1-8	1.6	0
30	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: COAPT Trial. *JACC: Heart Failure*, **2021**, 9, 559-567	7.9	0
29	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. *Journal of the American Society of Echocardiography*, **2021**, 34, 955-965	5.8	0

28	Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia. *American Heart Journal* , **2022**, 243, 187-200	4.9	0
27	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD.. *Journal of the American Heart Association*, **2022**, e022003	6	0
26	Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 747511	5.4	0
25	Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.. *JACC: Cardiovascular Interventions*, **2022**, 15, 797-806	5	0
24	Reply: Delayed onset of novel P2Y12 receptor antagonists action post fibrinolysis. *International Journal of Cardiology*, **2017**, 234, 132	3.2	
23	ABSORB IV: will the low rate of scaffold thrombosis persist? - Authors' reply. *Lancet, The*, **2019**, 393, 2392-2393	42	
22	Defining Secondary Mitral Regurgitation: Evidence that the 2017 Updated Guidelines Got it Right. *Structural Heart*, **2019**, 3, 284-287	0.6	
21	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Inhibitor Pretreatment. *Circulation: Cardiovascular Interventions*, **2019**, 12, e007445	6	
20	Varying Responses to Antithrombotic Treatment by Race/Ethnicity--Reply. *JAMA - Journal of the American Medical Association*, **2015**, 314, 625	27.4	
19	Mortality risk with dual antiplatelet therapy? - Authors' reply. *Lancet, The*, **2015**, 386, 1535	40	
18	The year in review: advances in interventional cardiology in 2019. *Current Opinion in Cardiology*, **2020**, 35, 325-331	2.1	
17	How Cox models react to a study-specific confounder in a patient-level pooled dataset: random effects better cope with an imbalanced covariate across trials unless baseline hazards differ. *Journal of Applied Statistics*, **2019**, 46, 1903-1916	1	
16	Outcomes of a Combined Approach of Percutaneous Coronary Revascularization and Cardiac Valve Surgery. *Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery*, **2017**, 12, 4-8	1.5	
15	Reply: Race, Trials, and Intervention: Do We Need to Look Deeper?. *JACC: Cardiovascular Interventions*, **2020**, 13, 2311-2312	5	
14	Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial). *American Journal of Cardiology*, **2021**, 143, 21-28	3	
13	Pharmacotherapy in Stable Coronary Artery Disease: Historical Perspectives and New Insights from the ISCHEMIA Trial. *European Cardiology Review*, **2021**, 16, e04	3.9	
12	Response by Bangalore et al to Letter Regarding Article, "Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials". *Circulation*, **2021**, 143, e809-e810	16.7	
11	White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial. *Coronary Artery Disease*, **2022**, 31, 45-51	1.4	

10	Provisional Stenting of Coronary Bifurcations. *JACC Asia*, **2021**, 1, 65-67	
9	Implications of Biomarker Discordance After Coronary Artery Revascularization. *Journal of the American College of Cardiology*, **2021**, 77, 2978-2980	15.1
8	Outcomes of Patients With Coronary Arterial Bifurcation Narrowings Undergoing Provisional 1-Stent Treatment (from the BIONICS Trial). *American Journal of Cardiology*, **2020**, 126, 8-15	3
7	Revascularization Strategies for Calcified Lesions in Patients Presenting With Acute Coronary Syndromes (From the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). *Journal of Invasive Cardiology*, **2016**, 28, 10-6	0.7
6	Outcomes of Vascular Closure Device Use After Transfemoral Coronary Intervention: Insights From the EXCEL Trial. *Journal of Invasive Cardiology*, **2021**, 33, E619-E627	0.7
5	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. *Circulation: Cardiovascular Interventions*, **2022**, CIRCINTERVENTIONS121011069	6
4	Double-Blind, Placebo-Controlled Evaluation of Biorest Liposomal Alendronate in Diabetic Patients Undergoing PCI: The BLADE-PCI Trial: The BLADE-PCI Trial.. *American Heart Journal*, **2022**, 249, 45-45	4.9
3	In search of the "IDEAL" left main coronary stent and DAPT regimen.. *EuroIntervention*, **2022**, 17, 1457-1459	5.9
2	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy.. *Journal of the American College of Cardiology*, **2022**, 79, 1963-1965	15.1
1	Response to: Correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Armoiry and Connock.. *Heart*, **2022**,	5.1